Results 101 to 110 of about 25,272 (176)

Seismic Design of Concrete Dams: An Integrated Risk‐Informed Performance‐Based (RIPB) Framework

open access: yesEarthquake Engineering &Structural Dynamics, Volume 55, Issue 5, Page 1019-1049, 25 April 2026.
ABSTRACT This paper advances the integration of risk‐informed principles into the seismic design of dams—a domain long guided by standards‐based, largely deterministic approaches. While performance‐based earthquake engineering is well established for buildings and bridges, its systematic adoption in dam engineering remains limited. We first address two
M. Amin Hariri‐Ardebili, Larry K. Nuss
wiley   +1 more source

Mono(2‐Ethylhexyl) Phthalate Induces Inflammatory and Angiogenic Alterations Mediated by the PI3K/AKT Pathway in HTR‐8/SVneo Trophoblastic Cells

open access: yesEnvironmental Toxicology, Volume 41, Issue 4, Page 209-222, April 2026.
ABSTRACT Exposure to mono(2‐ethylhexyl) phthalate (MEHP) during pregnancy has been associated with adverse pregnancy and birth outcomes characterized by extravillous trophoblast (EVT) abnormal function. Previous reports have suggested that MEHP can activate the PI3K/AKT pathway in EVT cells, a pathway known to regulate inflammation and angiogenesis in ...
Luis Daniel Martínez‐Razo   +5 more
wiley   +1 more source

Universal Cytomegalovirus Screening in the First Trimester of Pregnancy: The Multicentre Observational Cohort Study in the Area of Barcelona (CITEMB Study)

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 5, Page 1037-1045, April 2026.
ABSTRACT Objective To determine the CMV seroprevalence among pregnant women and assess the rate of primary CMV infections during the first trimester. Design Prospective multicentre observational cohort study. Setting Four primary care centres (ASSIRs) and two tertiary hospitals in Barcelona and its metropolitan area. Pupulation or Sample Pregnant women
María Ángeles Sánchez‐Durán   +21 more
wiley   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli   +24 more
wiley   +1 more source

Finite Element Implementation of Delta-P1 Model for Simulation of Photothermal Cancer Therapy in Heterogeneous Tissues. [PDF]

open access: yesNanomaterials (Basel)
Gómez-Araque RC   +3 more
europepmc   +1 more source

Do's and Don'ts When Visiting Circularly Polarized Luminescence

open access: yesAdvanced Optical Materials, Volume 14, Issue 11, 20 March 2026.
This perspective presents our insights into the principles, challenges, and opportunities of circularly polarized luminescence (CPL). Highlighting key concepts such as the dissymmetry factor (glum) and molecular design strategies, we discuss advances in CPL efficiency, emerging NIR emitters, solid‐state applications, and the growing role of theory and ...
Rafael G. Uceda   +9 more
wiley   +1 more source

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. [PDF]

open access: yesBreast Cancer Res Treat
Tolosa P   +25 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy